Artelo Biosciences reports Q3 EPS (35c), consensus (46c)

“With the ongoing, rapid progress of our pipeline, we anticipate multiple clinical readouts over the next 15 months,” stated Gregory D. Gorgas, President and CEO of Artelo Biosciences (ARTL). “Starting with ART26.12, our promising Fatty Acid Binding Protein 5 inhibitor drug candidate, we received FDA clearance to begin trials in chemotherapy-induced peripheral neuropathy. This debilitating condition, for which there is no approved treatment, affects up to 40% of people experiencing chemotherapy. Phase 1 results are expected in the first half of 2025. Additionally, we presented data at several conferences during the quarter highlighting the promising effects of inhibiting FABP5 across multiple cancer types and cancer bone pain.”